Dexamethasone palmitate
PreclinicalSmall molecule
Dexamethasone palmitate is one of 54 small molecule programs targeting Chronic pain. It is currently in Preclinical.
3
Indications
8
Total Trials
4
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
77 competitors in Chronic Pain
#DrugCompanyPhaseTrials
1Marinol
Jazz PharmaceuticalsApproved
Intuniv
PPromius Pharma, LLC
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Pitocin
RRetrophin
Approved
Norpramin
VValidus Pharmaceuticals
Approved
Decadron
AAspen Global Incorporated
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Advil
KKenvue Brands
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Epsom Salt
FFresenius Kabi USA, LLC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Dexamethasone Palmitate3 trials
Dexamethasone Palmitate for PONV After Craniotomy
Recruiting·—·N/A·NCT06988124·500 enrolled
Preemptive Co-infiltration of Dexamethasone Palmitate With Ropivacaine for Postoperative Pain in Major Spinal Surgery
Completed·—·Phase 4·NCT05693467·124 enrolled
Dexamethasone Palmitate for PONV After Open Surgery
Recruiting·—·N/A·NCT06997419·500 enrolled
Chronic pain1 trial
Dexamethasone1 trial
REDUCE Trial: Perineural Dexamethasone on Scalp Nerve Blocks
Completed·—·N/A·NCT04648358·156 enrolled
Post-craniotomy1 trial
Scalp Infiltration With Dexamethasone Plus Ropivacaine for Post-craniotomy Pain
Unknown status·—·Phase 4·NCT04488315·130 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dexamethasone palmitate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- XXijing Hospital